COSCIENS Biopharma Overview
Latest PEG ratio for COSCIENS Biopharma: -0.36 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-0.36
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for CSCI is -0.36. That is above the sector sector average of -2.26. Investors often review this figure alongside COSCIENS Biopharma's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, CSCI currently prints -0.36 for PEG ratio, while the sector average sits near -2.26. That is roughly 83.9% above the sector mean. Large gaps often invite a closer look at COSCIENS Biopharma's growth, margins, and balance sheet.
A PEG ratio of -0.36 for COSCIENS Biopharma is not 'good' or 'bad' on its own. Compare it with the peer average (-2.26) and with CSCI's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting CSCI's PEG ratio (-0.36), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
